Stockscreener 앱 받기
74.84
6.16%
-4.93
전일 마감가:
$79.77
열려 있는:
$77.34
하루 거래량:
1.99M
Relative Volume:
0.28
시가총액:
$29.71B
수익:
$2.23B
순이익/손실:
$-3.19B
주가수익비율:
-9.1871
EPS:
-8.1462
순현금흐름:
$-1.60B
1주 성능:
+3.26%
1개월 성능:
+57.27%
6개월 성능:
+121.09%
1년 성능:
+130.06%
1일 변동 폭
$74.52
$78.30
1주일 범위
$73.68
$85.60
52주 변동 폭
$22.28
$85.60
모더나 Stock (MRNA) Company Profile
명칭
Moderna Inc
전화
(617) 714-6500
주소
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
74.88 | 31.65B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
515.25 | 132.55B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.42 | 70.90B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
917.64 | 57.21B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.02 | 42.94B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.72 | 40.49B | 742.00K | -1.37B | -1.07B | -7.0731 |
모더나 Stock (MRNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 재개 | Barclays | Equal Weight |
| 2026-01-07 | 재개 | UBS | Neutral |
| 2025-12-12 | 개시 | Jefferies | Hold |
| 2025-03-13 | 개시 | Citigroup | Neutral |
| 2025-02-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-01-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-12-18 | 다운그레이드 | Argus | Buy → Hold |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-19 | 개시 | Berenberg | Hold |
| 2024-11-18 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-11-15 | 개시 | Wolfe Research | Underperform |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-09-13 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-09-13 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-09-13 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-08-28 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-08-07 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-08-05 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2024-01-02 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-11-29 | 개시 | Canaccord Genuity | Hold |
| 2023-11-03 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2023-11-02 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2023-08-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-07-24 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-06-26 | 업그레이드 | UBS | Neutral → Buy |
| 2023-04-26 | 개시 | Guggenheim | Neutral |
| 2023-03-13 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | 개시 | RBC Capital Mkts | Outperform |
| 2023-02-24 | 다운그레이드 | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-12-14 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2022-02-01 | 업그레이드 | Redburn | Sell → Neutral |
| 2022-01-26 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2022-01-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-01-21 | 개시 | UBS | Neutral |
| 2021-12-07 | 개시 | Cowen | Market Perform |
| 2021-11-09 | 개시 | Wolfe Research | Outperform |
| 2021-10-22 | 개시 | Deutsche Bank | Sell |
| 2021-10-15 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-08-06 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | 재확인 | Jefferies | Hold |
| 2021-02-01 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-12-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-12-16 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | 다운그레이드 | Needham | Buy → Hold |
| 2020-11-23 | 개시 | Wells Fargo | Equal Weight |
| 2020-11-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | 개시 | SVB Leerink | Mkt Perform |
| 2020-07-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-07-13 | 개시 | Jefferies | Buy |
| 2020-06-30 | 개시 | Argus | Buy |
| 2020-06-08 | 개시 | Barclays | Overweight |
| 2020-04-30 | 개시 | BMO Capital Markets | Outperform |
| 2020-03-05 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | 재개 | BofA/Merrill | Buy |
| 2019-10-25 | 개시 | ROTH Capital | Buy |
| 2019-04-05 | 개시 | Chardan Capital Markets | Buy |
모두보기
모더나 주식(MRNA)의 최신 뉴스
Moderna adds former Biogen CFO to board of directors By Investing.com - Investing.com Canada
Former Biogen CFO Michael McDonnell joins Moderna (NASDAQ: MRNA) board and Audit Committee - Stock Titan
Moderna Appoints Michael McDonnell to Board of Directors - Eagle-Tribune
Moderna adds former Biogen CFO Michael McDonnell to its board - Stock Titan
Bank of America Securities Reaffirms Their Sell Rating on Moderna (MRNA) - The Globe and Mail
The Moderna Omicron XBB.1.5 vaccine. Updated booster targets current variants - AD HOC NEWS
Meitav Investment House Ltd. Sells 16,067 Shares of Moderna, Inc. $MRNA - MarketBeat
Hsbc Holdings PLC Sells 107,077 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna Stock Surges 37%, With A 6-Day Winning Spree - Trefis
Moderna Stock On Fire: Up 37% With 6-Day Winning Streak - Trefis
Form 4 Moderna Inc For: 7 July By Investing.com - Investing.com Canada
Moderna (MRNA) Chief Commercial Officer awarded RSUs and stock options - Stock Titan
MRNA Maintained by RBC Capital -- Price Target Raised to $45 - GuruFocus
MRNA Maintained by B of A Securities -- Price Target Raised to $38 - GuruFocus
Strs Ohio Acquires 68,887 Shares of Moderna, Inc. $MRNA - MarketBeat
RBC Capital Adjusts Moderna Price Target to $45 From $38, Maintains Sector Perform Rating - marketscreener.com
Moderna Stock Is Soaring. Is It Too Late to Buy? - The Motley Fool
ABUS Stock Rallies Ahead Of Big Payout From Moderna Settlement This Week - Stocktwits
Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
Moderna (MRNA) CFO reports RSU vesting, tax-withheld shares on Form 4 - Stock Titan
Moderna (NASDAQ:MRNA) Vaccine Momentum Turns Heads - Kalkine Media
Moderna shares rise as investors continue to digest pipeline expansion and flu vaccine progress - Quiver Quantitative
Why Moderna Inc (MRNA) May Struggle to Outperform: A Look at Fut - GuruFocus
Moderna stock hits 52-week high at 81.42 USD - Investing.com
17,700 Shares in Moderna, Inc. $MRNA Bought by Louisiana State Employees Retirement System - MarketBeat
Price to sales forward of Moderna, Inc. – NASDAQ:MRNA - TradingView
MRNA Stock Quote Price and Forecast - CNN
Moderna | History, Innovation, Challenges, & Facts - Encyclopedia Britannica
Jim Cramer Turns Bullish on Moderna After 150% Rally, Citing Cancer Pipeline and Flu Vaccine Momentum - finance.biggo.com
Jim Cramer Says “For the First Time in Ages, I Like Having a Position in Moderna” - Yahoo Finance
MRNAModerna Inc Latest SEC Filings - Finviz
Moderna Stock (MRNA) Opinions on mRNA Flu Vaccine Approval and Stock Surge - Quiver Quantitative
Moderna Is Up More Than 70% in a Month After a 9-0 FDA Vote. Wall Street's Average Price Target Says It Should Fall 44%. What Gives? - The Globe and Mail
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026? - The Motley Fool
MRNA Stock on the Move: What Sparked the 33.5% Jump in the Past Week? - TradingView
Jim Cramer turns bullish on health care stock after years of doubt - thestreet.com
Trump's Newly Disclosed Moderna Trades Preceded FDA Advisory Panel's Unanimous Backing of MRNA Flu Vaccine - Moomoo
Moderna (NASDAQ:MRNA) gains $2.9 billion as investors pile into flu push, beating 2025 revenue - TechStock²
Tesla, Rivian, Strategy, Moderna, Sandisk, Blue Owl, and More Stocks That Explain Today’s Market - Barron's
MRNA Stock Surges As Flu Win And CAR-T Hype Fuel Breakout - StocksToTrade
Trump’s Newly Disclosed Moderna Trades Preceded FDA Advisory Panel’s Unanimous Backing of mRNA Flu Vaccine - Quiver Quantitative
MRNA Stock Surges As Flu Vaccine Win Fuels Pipeline Hype - StocksToTrade
Moderna COVID-19 Vaccine SpikevaxCompany bets on booster demand in US clinics - AD HOC NEWS
Why Moderna Is Today’s Top S&P 500 Stock - Barron's
The Spikevax Bivalent Original/Omicron COVID-19 VaccineModerna Inc. targets booster demand in the - AD HOC NEWS
Short Squeeze Alert—Moderna Stock Surges on New Strategy - MarketBeat
Pictet Asset Management Holding SA Has $32.79 Million Stock Holdings in Moderna, Inc. $MRNA - MarketBeat
Moderna (MRNA) Chief Commercial Officer files baseline Form 3 insider statement - Stock Titan
Is Moderna Stock a No-Brainer Buy After a Key FDA Win? - The Globe and Mail
Moderna Inc. mRESVIA targets older adults with a one-dose RSV shot - AD HOC NEWS
ETFs Investing in Moderna, Inc. Stocks - TradingView
모더나 (MRNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
모더나 주식 (MRNA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Hoge Stephen | President |
Jun 15 '26 |
Option Exercise |
19.15 |
53,336 |
1,021,384 |
1,537,184 |
| Hoge Stephen | President |
Jun 15 '26 |
Sale |
51.37 |
53,336 |
2,739,870 |
1,483,848 |
1.63%
2.63%
자본화:
|
볼륨(24시간):